 Home > Active Ingredient News > Antitumor Therapy > Blood: Outcome after failure of anti-CD19 CAR-T cell therapy in patients with aggressive B-cell lymphoma

Blood: Outcome after failure of anti-CD19 CAR-T cell therapy in patients with aggressive B-cell lymphoma

 Last Update: 2022-10-12
 Source: Internet
 Author: User

Tags

blood clotting mechanism

isogenic cell lines

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Anti-CD19 CAR-T cell therapy represents a major advance

At the time of registration, 57.

After CAR-T cell therapy failed, 154 (64%) patients received salvage therapy: 38.

The median overall survival of patients who failed treatment with D0-D30 and failed treatment after D30 was 1.

In the multivariate analysis, the multicenter analysis of elevated LDH at infusion and time to CAR-T therapy failure confirmed the poor prognosis of recurrence in patients after CAR-T cell therapy, emphasizing the need for further strategies to target this population

Original Source:

Roberta Di Blasi, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Blood: Outcomes in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR-T cell therapy

09-30

Related Products

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

High Quality Resveratrol 99% powder 501-36-0 Shaanxi Dideu Medichem Co.Ltd

CAS No.: 501-36-0

Chemical Grade

$1/KG FOB

High purity Epirubicin hydrochloride 98% with best price 56390-09-1 and Epirubicin hydrochloride raw powder

CAS No.: 56390-09-1

Pharmacy Grade

$8.8-10/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Blood: Outcome after failure of anti-CD19 CAR-T cell therapy in patients with aggressive B-cell lymphoma

Related Articles

Blood: Outcomes in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR-T cell therapy